Navigation Links
Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials
Date:3/20/2008

Wows Rome audience with live study setup and launch...

WAYLAND, Mass., March 20 /PRNewswire/ -- Tourtellotte Solutions, a global leader in bio-pharmaceutical clinical trials software, announces the launch of its Trident IWR(TM) next-generation IWR/IVRS platform for phase II-IV studies. Trident's unique parameter driven + custom pluggable design leaps ahead of legacy IVRS technologies and promises to deliver a new era of needed scalability, productivity, and ease-of-use to the straining global clinical IVRS market.

Tourtellotte representatives demonstrated the next-generation Trident IWR, fully integrated with the tcVisualize(TM) clinical supply simulator, to an appreciative audience at the VIB Clinical Supply Europe conference in Rome, Italy on February 25th, 2008.

Clinical IVRS (or IWR) systems are the source and driver of patient randomization, drug dispensing, and trial supply logistics, and as such are critical to the multi-center clinical trials that they support. Having grown up from older telephony-based technology and designs, however, current IVRS platforms are difficult to scale, and time consuming to set up. Some estimates put the industry standard programming time for a new clinical trial in IVRS to be 8-12 weeks, with commensurate cost, risk and technical design and validation overhead.

A parameter driven IWR such as Trident can eliminate this lead-time and a host of other difficulties due to its parameterized design, coupled with automatic 2-way integration with trial simulators such as tcVisualize. The Tourtellotte team in Rome demonstrated this concept by soliciting a live study design from the audience, then setting up and simulating the study in tcVisualize, and exporting the study to Trident. After switching on the study in Trident IWR, the TS team then acted as a clinical site to screen, randomize, and dose subjects, and then brought the data back into tcVisualize to show end to end study design, launch,
'/>"/>

SOURCE Tourtellotte Solutions
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Discovery Institute Bioethicist Lauds Breakthrough in Stem Cells Research that Eliminates Need for Human Cloning
2. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
3. C1-Esterase Inhibitor Concentrate Rapidly Relieves Abdominal and Facial Attacks in Patients with Hereditary Angioedema, According to Pivotal Study
4. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
5. Diamyd Gets Authorization to Begin Phase III Study in the US
6. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
7. Study Finds Broadband Access Key to Empowerment of Minority Communities
8. Raven Announces RAV12 Phase 1/2a Study Results To Be Presented at ASCO
9. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
10. Fralex reaches 100th patient milestone in fibromyalgia study
11. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... & Rockville, MD (PRWEB) August 21, 2014 ... (ITI) is making progress in its development of JRC-LAMP-vax, ... Japanese red cedar pollen. Phase IC studies began this ... real solution to hay fever. , The Japanese red ... 35 million people in Japan. Mountain Cedar pollen wreaks ...
(Date:8/21/2014)... Emmetsburg, IA (PRWEB) August 21, 2014 ... Project LIBERTY Opening , The Court of His Majesty ... King will attend the Grand Opening of POET-DSM Advanced ... on Wednesday, Sept. 3. , The King will take ... formal opening activity, scheduled for 11 a.m.-12:20 p.m. and ...
(Date:8/21/2014)... 21, 2014 OTC Markets Group ... a biotechnology company, on its approval to list ... on OTCQX®, the best marketplace for established U.S. ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... execution of its growth strategy and achievement of ...
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... (Amex:,SGN) has announced that the legendary Earvin "Magic" ... ambulatory heart testing with AFL,s,flagship choice, Signalife,s Fidelity ... the greatest basketball superstars of all time, Mr.,Johnson ... multiple,championships from college to the Los Angeles Lakers ...
... September 13, 2007 at the 14th, International Symposium on Hepatitis C ... ... Glasgow, Scotland, VALLEY COTTAGE, New York, September 6 XTL,Biopharmaceuticals ... a late breaker abstract, entitled "Potent Small Molecule HCV,Inhibitors Affecting NS5A-dependent ...
... They,ve gotten the science wrong. They,ve gotten the law wrong. Why ... we trust them ... Coalition for,Lifesaving Cures responded today as opponents of stem cell cures ... weeks. Said Donn Rubin, Chair of Missouri Coalition for Lifesaving ...
Cached Biology Technology:Legendary Earvin 'Magic' Johnson Joins AFL/Signalife Cardiovascular Protection Team 2Legendary Earvin 'Magic' Johnson Joins AFL/Signalife Cardiovascular Protection Team 3XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference 23 strikes, you're out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause 2
(Date:8/22/2014)... to important discoveries in basic and clinical research ... mobilized into a complex offensive spanning multiple fronts. ... chemistry lab could help find new and more ... compound that targets a specific enzyme overexpressed in ... cells from brain tumours. , Chemistry professor Christopher ...
(Date:8/22/2014)... American consumers will finally be able to purchase fuel ... as zero-emissions vehicles, most of the cars will run ... that contributes to global warming. , Now scientists at ... uses an ordinary AAA battery to produce hydrogen by ... through two electrodes that split liquid water into hydrogen ...
(Date:8/21/2014)... , Aug. 21, 2014 Nxt-ID, Inc. ... growing mobile commerce market, announced today that its shares ... stock to be issued in its proposed underwritten public ... for listing on The Nasdaq Capital Market, subject to ... common stock and warrants, and will trade under the ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Stanford scientists develop a water splitter that runs on an ordinary AAA battery 2Stanford scientists develop a water splitter that runs on an ordinary AAA battery 3Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3
... a paradox that,s puzzled scientists for a half-century. ... depends on those species responding differently to the availability ... species draw a blank? Competitors like black gums ... shaded understories of eastern U.S. forests, yet species-level data ...
... for the study of stem cells and to increase capacity ... initiatives announced today by NIH Director Francis S. Collins, M.D., ... Common Fund, which encourages collaborative research programs across the NIH ... single IC could do alone. The programs are all scheduled ...
... , ... ... ... , ...
Cached Biology News:Forest tree species diversity depends on individual variation 2Forest tree species diversity depends on individual variation 3Emerging science, tech advances highlight new NIH Common Fund programs 2Emerging science, tech advances highlight new NIH Common Fund programs 3Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 2Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 3Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 4Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 5Aware, Inc. Joins HIMSS10 Interoperability Showcase to Demonstrate Standards-Based Medical Image Sharing 6
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Request Info...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Biology Products: